Radiant Clinical Research is expanding the scope of its Central Nervous System (CNS) studies. This expansion is in response to a growing need for qualified sites that have the expertise to conduct pharmaceutical trials for the treatment of schizophrenia, bipolar disorder, depression, Alzheimer’s and other CNS conditions.
To lead the expansion, Radiant has named Elizabeth Harley as the Director of Clinical Operations for CNS. Harley has more than 18 years of clinical research experience, most recently serving as Director of Business Development. In her new role, she will lead business development initiatives for Radiant’s CNS sites—working with both emerging and established companies.
“During her tenure in the industry, Elizabeth has developed strong collaborative relationships with key professionals, including pharmaceutical sponsors, CROs and biotechnology organizations,” said Mark Hanley, CEO of Radiant Clinical Research. “Her expertise lies in working with clients in early through late phase development. We are happy to have her lead this expansion.”
To date, Radiant Clinical Research has conducted over 1,800 phase I-IV CNS protocols and enrolled more than 35,000 patients in those studies. “Radiant’s Principal Investigators have collaboratively conducted the most CNS research in the industry,” said Elizabeth Harley. “I am proud to work with this accomplished team to continue to make an impact on the future of CNS treatments.” Harley also noted that Drs. Marandi, Lowy, and Vallanat have been involved with every major psychotropic medication approved in the past 20 years.
Radiant’s CNS sites are located in Queens, NY; Atlanta, GA; Salt Lake City, UT; Cerritos, CA; Washington, D.C.; San Antonio TX; and Gilbert, AZ. The sites provide pharmaceutical and biotechnology sponsors with rapid study startup, reliable enrollment and high quality data for all phases of clinical trials in CNS populations.